Alexion Pharmaceuticals (France)
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid li
Basic Information
- Category: business
- Website: http://www.alexion.com/SelectCountry/France.aspx
Documented Facts
- Headquarters: Boston, Massachusetts that specializes in orphan drugs to treat rare diseases (No linked source recorded for this statement.)
- Parent company: AstraZeneca (No linked source recorded for this statement.)
Evidence and Sources
- Alexion Pharmaceuticals (France) — Wikipedia (reference)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Alexion Pharmaceuticals (France).
- Canonical profile: https://brandsource.ai/brands/alexion-pharmaceuticals-france
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/alexion-pharmaceuticals-france/json-ld
- Citation profile API: https://brandsource.ai/api/brands/alexion-pharmaceuticals-france/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (70/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid li
Available profile information
- Official website is captured for entity disambiguation.
- 1 supporting source linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.